BLK - Wiki-Pi

Search Results for: BLK

Can't find the interaction you're looking for? Try the advanced search

56 interactions involving BLK - BLK proto-oncogene, Src family tyrosine kinase found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases

Symbol	Description	Pathways Hide	Drugs Hide	Diseases Hide
ERBB3	erb-b2 receptor tyrosine kinase 3		Tucatinib	Type I diabetes mellitus Lethal congenital contractural syndrome (LCCS)
ERBB4	erb-b2 receptor tyrosine kinase 4		Afatinib Fostamatinib Brigatinib Zanubrutinib
FBXO7	F-box protein 7	Neddylation Antigen processing: Ubiquitination & Proteasome degradation		Parkinson's disease (PD)
FCGR2A	Fc gamma receptor IIa	FCGR activation FCGR activation Regulation of actin dynamics for phagocytic cup formation Role of phospholipids in phagocytosis Neutrophil degranulation FCGR3A-mediated IL10 synthesis	Cetuximab Etanercept Human immunoglobulin G Abciximab Alemtuzumab Daclizumab Bevacizumab Catumaxomab Sarilumab	Systemic lupus erythematosus
FCGR2B	Fc gamma receptor IIb	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	Etanercept Human immunoglobulin G Abciximab Tositumomab Alemtuzumab Antithymocyte immunoglobulin (rabbit) Palivizumab Daclizumab Bevacizumab Sarilumab	Systemic lupus erythematosus
FLACC1	flagellum associated containing coiled-coil domains 1
FXR1	FMR1 autosomal homolog 1	Signaling by BRAF and RAF1 fusions
FXR2	FMR1 autosomal homolog 2
GAB1	GRB2 associated binding protein 1	PI3K Cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PIP3 activates AKT signaling GAB1 signalosome PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PI3K/AKT signaling RET signaling MET activates PTPN11 MET activates RAP1 and RAC1 MET receptor recycling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Activated NTRK2 signals through PI3K Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants
GRB10	growth factor receptor bound protein 10	Signaling by SCF-KIT IRS activation Signal attenuation Insulin receptor signalling cascade RET signaling FLT3 Signaling Response of EIF2AK1 (HRI) to heme deficiency
HSF2BP	heat shock transcription factor 2 binding protein
IKZF3	IKAROS family zinc finger 3
JAKMIP1	janus kinase and microtubule interacting protein 1
KIT	KIT proto-oncogene, receptor tyrosine kinase	PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Regulation of KIT signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Dasatinib-resistant KIT mutants Imatinib-resistant KIT mutants KIT mutants bind TKIs Masitinib-resistant KIT mutants Nilotinib-resistant KIT mutants Regorafenib-resistant KIT mutants Signaling by kinase domain mutants of KIT Sunitinib-resistant KIT mutants Signaling by juxtamembrane domain KIT mutants Sorafenib-resistant KIT mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by extracellular domain mutants of KIT Transcriptional and post-translational regulation of MITF-M expression and activity Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Sorafenib Imatinib Dasatinib Sunitinib Phosphonotyrosine Nilotinib XL820 OSI-930 Linifanib Pazopanib Midostaurin Regorafenib Ponatinib Lenvatinib Ancestim Tivozanib Fostamatinib Erdafitinib Amuvatinib Pexidartinib Ripretinib Avapritinib	Acute myeloid leukemia (AML) Piebaldism
MET	MET proto-oncogene, receptor tyrosine kinase	PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D mediated inhibition of cell attachment and migration RAF/MAP kinase cascade MET Receptor Activation Negative regulation of MET activity PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates RAS signaling MET activates PI3K/AKT signaling MET activates PTPN11 MET activates PTK2 signaling InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell MET interacts with TNS proteins MET activates RAP1 and RAC1 MET receptor recycling MET activates STAT3 MECP2 regulates neuronal receptors and channels Drug-mediated inhibition of MET activation Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Sunitinib K-252a SGX-523 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol AMG-208 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE Crizotinib Cabozantinib Capmatinib Tivozanib Fostamatinib Tivantinib Brigatinib Amuvatinib Tepotinib Amivantamab	Cholangiocarcinoma Gastric cancer Renal cell carcinoma
MID2	midline 2
PICK1	protein interacting with PRKCA 1	Cell surface interactions at the vascular wall Trafficking of GluR2-containing AMPA receptors
PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	PI3K Cascade IRS-mediated signalling GPVI-mediated activation cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K events in ERBB4 signaling PIP3 activates AKT signaling Interleukin-7 signaling Interleukin-7 signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane GAB1 signalosome Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction PI3K events in ERBB2 signaling PI3K/AKT activation Signaling by ALK Downstream TCR signaling Role of phospholipids in phagocytosis Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions CD28 dependent PI3K/Akt signaling G alpha (q) signalling events GP1b-IX-V activation signalling VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway Interleukin-3, Interleukin-5 and GM-CSF signaling Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PI3K/AKT signaling RET signaling RHOA GTPase cycle Extra-nuclear estrogen signaling RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOD GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RHOU GTPase cycle RAC3 GTPase cycle RHOV GTPase cycle Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Activated NTRK2 signals through PI3K RHOF GTPase cycle Interleukin receptor SHC signaling Regulation of signaling by CBL Regulation of signaling by CBL Activated NTRK3 signals through PI3K FLT3 Signaling FLT3 Signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by CSF1 (M-CSF) in myeloid cells RND3 GTPase cycle RND2 GTPase cycle RND1 GTPase cycle Signaling by FLT3 fusion proteins Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Signaling by LTK in cancer Signaling by LTK Co-stimulation by ICOS	SF1126 Enzastaurin Wortmannin
PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	GPVI-mediated activation cascade PIP3 activates AKT signaling Interleukin-7 signaling Interleukin-7 signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane Constitutive Signaling by Aberrant PI3K in Cancer CD28 dependent PI3K/Akt signaling G alpha (q) signalling events Interleukin-3, Interleukin-5 and GM-CSF signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RET signaling Extra-nuclear estrogen signaling RAC1 GTPase cycle RAC2 GTPase cycle Interleukin receptor SHC signaling Regulation of signaling by CBL Regulation of signaling by CBL Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Co-stimulation by ICOS	SF1126
PLCG2	phospholipase C gamma 2	GPVI-mediated activation cascade Toll Like Receptor 4 (TLR4) Cascade Synthesis of IP3 and IP4 in the cytosol Generation of second messenger molecules Role of phospholipids in phagocytosis DAP12 signaling FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization CLEC7A (Dectin-1) signaling CLEC7A (Dectin-1) signaling Dectin-2 family Dectin-2 family Erythropoietin activates Phospholipase C gamma (PLCG) FCGR3A-mediated IL10 synthesis Potential therapeutics for SARS Signaling by CSF1 (M-CSF) in myeloid cells Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers

Page 2 out of 3 pages